Puma Biotechnology, Inc. (NASDAQ:PBYI) CEO Alan H. Auerbach Sells 33,841 Shares

Puma Biotechnology, Inc. (NASDAQ:PBYI) CEO Alan H. Auerbach sold 33,841 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $3.15, for a total value of $106,599.15. Following the completion of the transaction, the chief executive officer now owns 7,029,674 shares of the company’s stock, valued at approximately $22,143,473.10. This represents a 0.48 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Puma Biotechnology Stock Performance

NASDAQ PBYI traded down $0.17 during trading on Friday, reaching $2.95. 844,494 shares of the company’s stock were exchanged, compared to its average volume of 763,397. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.42 and a quick ratio of 1.40. The business has a 50 day moving average price of $2.99 and a 200-day moving average price of $2.98. The stock has a market capitalization of $144.81 million, a P/E ratio of 6.15 and a beta of 1.08. Puma Biotechnology, Inc. has a fifty-two week low of $2.22 and a fifty-two week high of $7.73.

Puma Biotechnology (NASDAQ:PBYI) last posted its earnings results on Thursday, November 7th. The biopharmaceutical company reported $0.41 earnings per share for the quarter, topping analysts’ consensus estimates of $0.31 by $0.10. Puma Biotechnology had a return on equity of 41.60% and a net margin of 9.56%. The business had revenue of $80.50 million for the quarter, compared to analyst estimates of $71.32 million. During the same period in the previous year, the firm earned $0.12 EPS. Sell-side analysts forecast that Puma Biotechnology, Inc. will post 0.31 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Puma Biotechnology

Several large investors have recently modified their holdings of the stock. JPMorgan Chase & Co. increased its stake in shares of Puma Biotechnology by 169.5% during the third quarter. JPMorgan Chase & Co. now owns 48,493 shares of the biopharmaceutical company’s stock worth $124,000 after purchasing an additional 30,499 shares during the period. Franklin Resources Inc. acquired a new position in shares of Puma Biotechnology in the third quarter valued at about $41,000. Virtu Financial LLC bought a new position in Puma Biotechnology during the third quarter worth about $68,000. Barclays PLC raised its stake in Puma Biotechnology by 146.5% in the 3rd quarter. Barclays PLC now owns 78,021 shares of the biopharmaceutical company’s stock worth $199,000 after purchasing an additional 46,370 shares in the last quarter. Finally, Jane Street Group LLC boosted its holdings in Puma Biotechnology by 103.9% in the 3rd quarter. Jane Street Group LLC now owns 32,129 shares of the biopharmaceutical company’s stock valued at $82,000 after purchasing an additional 16,374 shares during the period. 61.29% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently commented on PBYI. StockNews.com downgraded Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a report on Friday, December 6th. HC Wainwright reiterated a “buy” rating and issued a $7.00 price target on shares of Puma Biotechnology in a research note on Monday, December 23rd.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.